05/03/16 - 10:03 AM EDT
A number of factors help explain the less-than-celebratory reaction to the approval of Acadia Pharma's first drug, Nuplazid.
04/28/16 - 01:30 PM EDT
Thursday's parade of deals seem to answer a question that's been bugging health care investors for most of 2016: why haven't retreating biotech valuations sparked an uptick in M&A activity?
04/28/16 - 10:17 AM EDT
Senior FDA officials, most notably Dr. Janet Woodcock, the agency's top drug evaluator, spent a lot of time at Monday's panel making supportive statements about eteplirsen.
04/28/16 - 07:00 AM EDT
The French pharmaceuticals company takes its campaign to snare the oncology specialist public.
04/27/16 - 05:03 PM EDT
Vertex Pharmaceuticals tried to soothe fears about the commercial ramp of its cystic fibrosis franchise by providing Orkambi sales guidance for the first time since the drug launched last summer.
04/27/16 - 07:35 AM EDT
MannKind is drowning in debt and fixed purchasing contracts but the company generates no revenue.
04/25/16 - 07:34 AM EDT
An advisory committee convened by the U.S. Food and Drug Administration is reviewing Sarepta's experimental Duchenne muscular dystrophy drug.
04/24/16 - 12:46 PM EDT
The FDA advisory panel review of Sarepta's DMD drug eteplirsen will be surprising, controversial, volatile, dramatic, newsworthy and memorable.
04/22/16 - 08:31 AM EDT
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
04/21/16 - 09:58 AM EDT
The news was still negative for eteplirsen, the Duchenne muscular dystrophy drug from Sarepta Therapeutics.